2-aminobenzoylalanyl-glycyl-leucyl-alanyl-4-nitrobenzylamide: fluorogenic protease substrate [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 44144557 |
| MeSH ID | M0130769 |
| Synonym |
|---|
| aaglan |
| 100307-95-7 |
| l-alaninamide, n-(2-aminobenzoyl)-l-alanylglycyl-l-leucyl-n-((4-nitrophenyl)methyl)-, (6as-(6aalpha,7alpha,8beta,9aalpha))- |
| 2-aminobenzoyl-ala-gly-leu-ala-4-nitrobenzylamide |
| abz-ala-gly-leu-ala-nba |
| 2-aminobenzoylalanyl-glycyl-leucyl-alanyl-4-nitrobenzylamide |
| DTXSID80143126 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||